-
公开(公告)号：US20100324088A1
公开(公告)日：2010-12-23
申请号：US12866387
申请日：2009-02-04
IPC分类号： A61K31/47 , C07D221/04 , A61K31/455 , C07D215/56 , A61K31/4709 , C07D401/10 , A61P25/28 , A61P25/00 , A61P29/00
CPC分类号： C07D221/02 , C07D215/56 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/10 , C07D409/10 , C07D409/14 , C07D413/10
摘要： The present invention is directed to fused pyridone compounds of formula (I) (I) that are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及作为M1受体阳性变构调节剂的式（I）（I）的融合吡啶酮化合物，其可用于治疗涉及M1受体的疾病，例如阿尔茨海默病，精神分裂症，疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US08022215B2
公开(公告)日：2011-09-20
申请号：US12866387
申请日：2009-02-04
CPC分类号： C07D221/02 , C07D215/56 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/10 , C07D409/10 , C07D409/14 , C07D413/10
摘要： The present invention is directed to fused pyridone compounds of formula (I) (I) that are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及作为M1受体阳性变构调节剂的式（I）（I）的融合吡啶酮化合物，其可用于治疗涉及M1受体的疾病，例如阿尔茨海默病，精神分裂症，疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US08895580B2
公开(公告)日：2014-11-25
申请号：US13499335
申请日：2010-10-01
IPC分类号： A61K31/4745 , A61K31/5377 , C07D519/00 , C07D471/04 , C07D473/00 , C07D487/02 , C07D495/04 , A61K31/535
CPC分类号： C07D405/04 , A61K31/535 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/02 , C07D491/056 , C07D495/04 , C07F7/0812
摘要： The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及式（I）的喹啉酮 - 吡唑啉酮化合物，其为M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，例如阿尔茨海默氏病，精神分裂症，疼痛或睡眠障碍 。 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US20120196845A1
公开(公告)日：2012-08-02
申请号：US13499335
申请日：2010-10-01
IPC分类号： A61K31/4745 , A61K31/5377 , A61K31/496 , A61K31/506 , A61K31/519 , C07D519/00 , A61K31/498 , A61K31/52 , A61P25/28 , A61P25/18 , A61P29/00 , A61P25/00 , C07D471/04 , A61K31/501
CPC分类号： C07D405/04 , A61K31/535 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/02 , C07D491/056 , C07D495/04 , C07F7/0812
摘要： The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及式（I）的喹啉酮 - 吡唑啉酮化合物，其为M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，例如阿尔茨海默氏病，精神分裂症，疼痛或睡眠障碍 。 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US09139576B2
公开(公告)日：2015-09-22
申请号：US14115123
申请日：2012-04-30
申请人： Douglas C. Beshore , Robert M. Garbaccio , Scott D. Kuduk , Adam W. Johnson , Jason W. Skudlarek
发明人： Douglas C. Beshore , Robert M. Garbaccio , Scott D. Kuduk , Adam W. Johnson , Jason W. Skudlarek
IPC分类号： C07D413/12 , C07D401/14 , C07D403/10 , C07D249/18 , C07D401/10 , C07D401/12 , C07D413/10
CPC分类号： C07D413/12 , C07D249/18 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D413/10
摘要： The present invention is directed to aminomethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
摘要翻译： 本发明涉及作为代谢型谷氨酸受体，特别是mGluR2受体的增效剂的氨基甲基联芳基苯并三唑衍生物，其可用于治疗或预防与谷氨酸能力障碍相关的神经和精神病学障碍以及涉及代谢型谷氨酸受体的疾病 。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
-
公开(公告)号：US20130059860A1
公开(公告)日：2013-03-07
申请号：US13698288
申请日：2011-05-23
IPC分类号： A61K31/44 , A61K31/4433 , A61K31/4439 , A61K31/415 , A61K31/192 , C07D403/04 , C07D401/04 , C07D405/12 , C07D213/56 , C07D231/12 , C07C63/36 , A61P25/00 , A61P25/28 , A61P25/18 , A61K31/496
CPC分类号： A61K31/16 , A61K31/192
摘要： The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及作为M1受体阳性变构调节剂的式（I）的萘甲酰胺化合物，其可用于治疗涉及M1受体的疾病，例如阿尔茨海默病，精神分裂症，疼痛或睡眠障碍。 本发明还涉及包含该化合物的药物组合物以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US09206200B2
公开(公告)日：2015-12-08
申请号：US14117341
申请日：2012-05-11
IPC分类号： C07D519/00 , C07D417/04 , C07D471/08 , C07D401/14 , C07D405/14 , C07D401/06 , C07D401/08 , C07D403/06 , C07D403/08 , C07D417/08 , C07D471/04 , C07D487/08 , C07D491/10 , C07D209/64
CPC分类号： C07D519/00 , C07D209/64 , C07D401/06 , C07D401/08 , C07D401/14 , C07D403/06 , C07D403/08 , C07D405/14 , C07D417/08 , C07D471/04 , C07D471/08 , C07D487/08 , C07D491/10
摘要： The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及通式（I）的N-连接的内酰胺类化合物，其为M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，例如阿尔茨海默病，精神分裂症，疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
8.发明授权公开(公告)号：US08293744B2
公开(公告)日：2012-10-23
申请号：US13264267
申请日：2010-04-13
申请人： Scott D. Kuduk , Douglas C. Beshore
发明人： Scott D. Kuduk , Douglas C. Beshore
IPC分类号： A61K31/50 , C07D237/36
CPC分类号： C07D471/14 , C07D495/14
摘要： The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及式（I）的杂环稠合噌啉化合物，其为M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，例如阿尔茨海默氏病，精神分裂症，疼痛或睡眠障碍 。 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
公开(公告)号：US20120135977A1
公开(公告)日：2012-05-31
申请号：US13247009
申请日：2011-09-28
申请人： Douglas C. Beshore , Vadim Dudkin , Robert M. Garbaccio , Adam W. Johnson , Scott D. Kuduk , Jason W. Skudlarek , Cheng Wang , Mark E. Fraley
发明人： Douglas C. Beshore , Vadim Dudkin , Robert M. Garbaccio , Adam W. Johnson , Scott D. Kuduk , Jason W. Skudlarek , Cheng Wang , Mark E. Fraley
IPC分类号： A61K31/4192 , C07D401/12 , A61K31/4439 , C07D403/12 , A61K31/506 , A61K31/497 , C07D471/04 , A61K31/437 , A61K31/496 , C07D413/12 , A61K31/5377 , A61K31/454 , A61K31/551 , A61K31/55 , C07D417/12 , A61K31/541 , A61P25/00 , A61P25/18 , C07D249/18
CPC分类号： C07D249/18 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
-
公开(公告)号：US20150065498A1
公开(公告)日：2015-03-05
申请号：US14117341
申请日：2012-05-11
IPC分类号： C07D519/00 , C07D471/04 , C07D471/08 , C07D209/64 , C07D403/06 , C07D405/14 , C07D401/14 , C07D401/06
CPC分类号： C07D519/00 , C07D209/64 , C07D401/06 , C07D401/08 , C07D401/14 , C07D403/06 , C07D403/08 , C07D405/14 , C07D417/08 , C07D471/04 , C07D471/08 , C07D487/08 , C07D491/10
摘要： The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译： 本发明涉及通式（I）的N-连接的内酰胺类化合物，其为M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，例如阿尔茨海默病，精神分裂症，疼痛或 睡眠障碍 本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.031 秒)